Knights of Columbus Asset Advisors’s Intellia Therapeutics NTLA Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,402	Closed	-$42.7K	–	396
2023 Q4	$42.7K	Buy	1,402 +380	+37%	+$10.9K	﹤0.01%	361
2023 Q3	$32.3K	Buy	1,022 +88	+9%	+$3.41K	﹤0.01%	364
2023 Q2	$38.1K	Sell	934 -5,839	-86%	-$237K	﹤0.01%	363
2023 Q1	$252K	Sell	6,773 -11,291	-63%	-$443K	0.02%	292
2022 Q4	$630K	Sell	18,064 -294	-2%	-$14K	0.07%	247
2022 Q3	$1.03M	Buy	+18,358	New	+$1.14M	0.1%	221

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Knights of Columbus Asset Advisors's NTLA Position: Q1 2024 in Review

Knights of Columbus Asset Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 1,402 shares — an estimated $42.7K sold.

Knights of Columbus Asset Advisors first reported a position in NTLA in Q3 2022 and held it in 6 quarters. The position peaked at $1.03M in Q3 2022. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Knights of Columbus Asset Advisors reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 1,402 Intellia Therapeutics shares in Q1 2024, an estimated $42.7K.
Knights of Columbus Asset Advisors first reported a position in Intellia Therapeutics in Q3 2022 and held it in 6 quarters.
Knights of Columbus Asset Advisors's Intellia Therapeutics position peaked at $1.03M in Q3 2022.
285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2024, filed 10 May 2024.